Results 131 to 140 of about 26,552 (294)

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Additive Glucagonotropic and Insulinotropic Effects of Glucose‐Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims/Hypothesis Glucose‐dependent insulinotropic polypeptide (GIP) is a bidirectional glucose‐stabilising hormone potentiating insulin secretion at high glucose levels and glucagon secretion during normal‐to‐low plasma glucose levels. Preclinically, GIP and the amino acid alanine show synergistic glucagonotropic effects at low glucose levels ...
Julie Warnøe, Aliya M. Thomas, David S. Mathiesen, Mathilde K. Preskou, Joachim Størling, Mikkel B. Christensen, Bolette Hartmann, Jens J. Holst, Samuel A. J. Trammell, Jonathan E. Campbell, Thomas F. Dejgaard, Asger B. Lund, Filip K. Knop, Lærke S. Gasbjerg   +13 more
wiley   +1 more source

Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires, Matheus Menezes‐Santos, Andréa Costa Goes, Heitor Siqueira Ribeiro, Luana Ferreira Alves, Beatriz Cruz dos Santos, Jéssyca Teles Barreto, Roberta Cristina Vieira Meneses, Ana Mara de Oliveira e Silva, Ana Hermínia Andrade e Silva, Sadraque Eneas de Figueiredo Lucena   +10 more
wiley   +1 more source

Transport of sulfonylurea herbicides from a barley field in Norway: Field and laboratory studies [PDF]

, 2008
Although the sulfonylurea herbicides have been used for many years worldwide, few field studies have been performed and little is known about the occurrence, fate and transport of sulfonylureas in the field.
Christiansen, Agnethe, Tveit, Cathrine Waage, Odenmarck, Sven R., Almvik, Marit, Børresen, Trond, Riise, Gunnhild, Bolli, Randi   +6 more
core  

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi, Reimar W. Thomsen, Carina Lundby, Jacob Volmer Stidsen, Kurt Højlund, Jesper Ryg, Mette Reilev, Anton Pottegård   +7 more
wiley   +1 more source

Characterization of sulfonylurea receptors in isolated human pancreatic islets

, 1998
Current information on pancreatic islet sulfonylurea receptors has been obtained with laboratory animal pancreatic beta cells or stable beta-cell lines.
GIANNACCINI, GINO, MARCHETTI, PIERO, MARTINI, CLAUDIA, DEL GUERRA S., LUPI R., NAVALESI R., BETTI, LAURA, TRINCAVELLI, MARIA LETIZIA, LUCACCHINI, ANTONIO   +8 more
core   +1 more source

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran, Hyung‐Seok Kim, Rozalina G. McCoy, Zafar Zafari   +3 more
wiley   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

Immunology, EarlyView.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac, Carolina do Prado Servian, Fernanda de Oliveira Feitosa de Castro, João Lucas Lima Calandrini de Azevedo, Ronaldo Moraes Preto, Miriam Leandro Dorta, Daniela Espíndola Antunes, Simone Gonçalves Fonseca   +7 more
wiley   +1 more source